Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement.
暂无分享,去创建一个
[1] H. Lynch,et al. Addressing Financial Barriers to Enrollment in Clinical Trials. , 2018, JAMA oncology.
[2] I. Cohen,et al. A Framework for Ethical Payment to Research Participants , 2018, The New England journal of medicine.
[3] Pengxiang Li,et al. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Mansfield,et al. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. , 2018, Journal of oncology practice.
[5] G. Samsa,et al. Out-of-Pocket Costs, Financial Distress, and Underinsurance in Cancer Care , 2017, JAMA oncology.
[6] J. Griggs,et al. Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Leblanc,et al. The impact of positive SWOG treatment trials on population survival. , 2017 .
[8] R. Pazdur,et al. Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials. , 2017, The New England journal of medicine.
[9] A. Jemal,et al. Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States , 2017, Cancer.
[10] N. Lin,et al. Prior Authorization for Medications in a Breast Oncology Practice: Navigation of a Complex Process. , 2017, Journal of oncology practice.
[11] Matthew P. Banegas,et al. Financial Hardships Experienced by Cancer Survivors: A Systematic Review , 2017, Journal of the National Cancer Institute.
[12] Suzanne M. Miller,et al. Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Jemal,et al. Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer Survivors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Newcomb,et al. Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Hang Lee,et al. Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. , 2016, The oncologist.
[16] Suzanne M. Miller,et al. Financial Concerns About Participation in Clinical Trials Among Patients With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Ramsey,et al. Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. , 2016, JAMA oncology.
[18] M. Newton,et al. Oral Antineoplastic Agents: Assessing the Delay in Care , 2015, Chemotherapy research and practice.
[19] C. Grady,et al. Clinical research: Should patients pay to play? , 2015, Science Translational Medicine.
[20] Laura A. Levit,et al. Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] B. Moy,et al. Recognizing the Financial Burden of Cancer Patients in Clinical Trials. , 2015, The oncologist.
[22] Juan Wisnivesky,et al. Geographic accessibility to clinical trials for advanced cancer in the United States. , 2015, JAMA internal medicine.
[23] Laura A. Levit,et al. American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Spencer E. Harpe,et al. Out-of-Pocket Costs and Oral Cancer Medication Discontinuation in the Elderly , 2014, Journal of managed care & specialty pharmacy.
[25] J. Griggs,et al. American Society of Clinical Oncology policy statement on medicaid reform. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] B. Moy,et al. Alleviating financial burden for cancer patients in clinical trials. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] C. Tangen,et al. Retention of Black and White Participants in the Selenium and Vitamin E Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S0000) , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[28] H. Kantarjian,et al. High cancer drug prices in the United States: reasons and proposed solutions. , 2014, Journal of oncology practice.
[29] Aaron N. Winn,et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Kurzrock,et al. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. , 2013, The oncologist.
[31] P. Newcomb,et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. , 2013, Health affairs.
[32] A. Abernethy,et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. , 2013, The oncologist.
[33] Katherine L Kahn,et al. Enrollment of patients with lung and colorectal cancers onto clinical trials. , 2013, Journal of oncology practice.
[34] A. Abernethy,et al. Financial toxicity, Part I: a new name for a growing problem. , 2013, Oncology.
[35] L. Minasian,et al. Effect of state-mandated insurance coverage on accrual to community cancer clinical trials. , 2012, Contemporary clinical trials.
[36] Nicole Martino,et al. Commonly performed procedures in clinical research: a benchmark for payment. , 2012, Contemporary clinical trials.
[37] G. Jacobson,et al. Medicare Advantage 2014 Spotlight: Enrollment Market Update , 2012 .
[38] Eric J Feuer,et al. Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.
[39] C. Rudin,et al. The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center , 2010, Clinical Cancer Research.
[40] E. Emanuel,et al. Clarifying Confusions about Coercion , 2005, The Hastings Center report.
[41] Ezekiel J Emanuel,et al. Undue Inducement: Nonsense on Stilts? , 2005, The American journal of bioethics : AJOB.
[42] Sarah M. Greene,et al. Organizational barriers to physician participation in cancer clinical trials. , 2005, The American journal of managed care.
[43] Harlan M Krumholz,et al. Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.
[44] M. Schonlau,et al. Incremental treatment costs in national cancer institute-sponsored clinical trials. , 2003, JAMA.
[45] D. Gandara,et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] L. Fehrenbacher,et al. Cost of care for patients in cancer clinical trials. , 2000, Journal of the National Cancer Institute.